PO.ADV01 · 患者倡导
肺癌生物标志物检测:推动精准治疗和改善结局
Lung cancer biomarker testing: Driving precision treatment and improved outcomes
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:生物标志物检测已成为现代肺癌管理的基石,可实现精准诊断、个体化治疗选择和持续监测。全面的分子谱分析现已指导非小细胞肺癌(NSCLC)和小细胞肺癌(SCLC)的治疗决策,改变了治疗结局并扩大了靶向和免疫疗法的可及性。目的:本海报重点介绍当前肺癌的生物标志物检测策略、关键基因组和免疫学标志物的临床意义,以及正在重塑实时疾病评估的新兴技术。内容概述:我们概述了关键的可采取行动的生物标志物——包括EGFR、ALK、ROS1、BRAF、MET外显子14跳跃、RET、NTRK和KRAS G12C——及其相关的靶向疗法。我们还讨论了免疫治疗相关的生物标志物,如PD-L1表达和肿瘤突变负荷(TMB),强调它们在预测检查点抑制剂应答中的作用。本海报概述了推荐的检测方法,包括基于组织的二代测序(NGS)、液体活检方法(ctDNA)以及可减少诊断延误的反射性检测方案。关键信息:广泛的分子检测可改善对可采取行动的变异的检出。免疫治疗生物标志物仍是应答的重要但不完美的预测指标。液体活检为初始检测和耐药监测提供了微创选择。整合多组学和AI辅助分析可能增强未来的决策。结论:全面的生物标志物检测对于在肺癌中实现精准肿瘤学至关重要。检测技术的进步、标准化工作以及流程的简化将进一步提高诊断准确性、临床决策水平,并最终改善患者结局。
查看英文原文 English abstract
Background: Biomarker testing has become a cornerstone ofmodern lung cancer management, enabling precise diagnosis, individualizedtherapy selection, and ongoing monitoring. Comprehensive molecular profilingnow guides treatment decisions for both non-small cell lung cancer (NSCLC) andsmall cell lung cancer (SCLC), transforming outcomes and expanding access totargeted and immune-based therapies. Objective: This poster highlights current biomarker testingstrategies in lung cancer, the clinical relevance of key genomic andimmunologic markers, and emerging technologies that are reshaping real-timedisease assessment. Content Overview: We present an overview of essentialactionable biomarkers-including EGFR, ALK, ROS1, BRAF, MET exon 14 skipping,RET, NTRK, and KRAS G12C-and their associated targeted therapies. We alsodiscuss immunotherapy-related biomarkers such as PD-L1 expression and tumormutational burden (TMB), emphasizing their role in predicting response tocheckpoint inhibitors. The poster outlines recommended testing methodologies,including tissue-based next-generation sequencing (NGS), liquid biopsy approaches(ctDNA), and reflex testing protocols that reduce diagnostic delays. Key Messages: Broad molecular testing improves detection ofactionable alterations. Immunotherapy biomarkers remain essential yet imperfectpredictors of response. Liquid biopsies provide minimally invasive options forinitial testing and resistance monitoring. Integrating multi-omics andAI-supported analytics may enhance future decision-making. Conclusion: Comprehensive biomarker testing is vital todelivering precision oncology in lung cancer. Advances in testing technologies,standardization efforts, and streamlined workflows will further improvediagnostic accuracy, clinical decision-making, and ultimately patient outcomes.